SCHEMBL256761

SCHEMBL256761

NCC(O)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382902 1.00
SCHEMBL424394 1.00
Hydrochloric Acid SCHEMBL20705297 0.97
Hydrochloric Acid SCHEMBL21193190 0.97
Hydrochloric Acid SCHEMBL8052344 0.97
SCHEMBL5181554 0.75
SCHEMBL19660402 0.75
SCHEMBL26618612 0.75
Hydrochloric Acid SCHEMBL12984147 0.73 CETP (0.57)
SCHEMBL459896 0.72 CETP (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867224-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-07-26 EP claimed
US-9388199-B2 Pyrrolidine derivatives and their use as complement pathway modulators NOVARTIS AG (CH) 2016-07-12 US claimed
EP-2547656-B1 PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF NOVARTIS AG (CH) 2015-09-30 EP claimed
US-20150166578-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2015-06-18 US claimed
EP-2867224-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS Novartis AG (CH) 2015-05-06 EP claimed
EP-2845593-A1 Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease Novartis AG (CH) 2015-03-11 EP claimed
WO-2014002053-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2014-01-03 WO claimed
WO-2010127975-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO claimed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US claimed
US-20090264411-A1 FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2009-10-22 US claimed
EP-1243576-B1 PROCESSES FOR PRODUCING (AMINOMETHYL)TRIFLUOROMETHYLCARBINOL DERIVATIVES DAINIPPON SUMITOMO PHARMA CO (JP) 2006-10-11 EP claimed
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP claimed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO claimed
US-6646150-B1 Reacting 1,3-oxazolidin-5-one derivative with trialkyl-(trifluoromethyl)silane; removing trialkylsilyl group; reductive decyclization DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2003-11-11 US claimed
EP-1243576-A1 PROCESSES FOR PRODUCING (AMINOMETHYL)TRIFLUOROCARBINOL DERIVATIVES Dainippon Pharmaceutical Co., Ltd. (JP) 2002-09-25 EP claimed
US-20260125383-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
US-20260108509-A1 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-04-23 US disclosed
EP-0040915-B1 ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS BEECHAM GROUP PLC (GB) 1984-03-21 EP disclosed
US-4385066-A DIETETICS, HYPERGLYCEMIC AGENTS ANTIINFLAMMATORY AGENTS BEECHAM GROUP LIMITED (GB) 1983-05-24 US disclosed
EP-0040915-A1 Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1981-12-02 EP disclosed